- Patent Title: Multivalent meningococcal polysaccharide-protein conjugate vaccine
-
Application No.: US15816211Application Date: 2017-11-17
-
Publication No.: US10143757B2Publication Date: 2018-12-04
- Inventor: Robert P. Ryall
- Applicant: Sanofi Pasteur Inc.
- Applicant Address: US PA Swiftwater
- Assignee: Sanofi Pasteur Inc.
- Current Assignee: Sanofi Pasteur Inc.
- Current Assignee Address: US PA Swiftwater
- Agency: Pierce Atwood LLP
- Agent Raymond G. Arner
- Main IPC: A61K39/095
- IPC: A61K39/095 ; A61K47/64 ; A61K39/116 ; A61K39/39 ; A61K47/24 ; A61K47/02 ; A61K47/08 ; A61K47/61 ; A61K39/00

Abstract:
The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.
Public/Granted literature
- US20180154010A1 Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine Public/Granted day:2018-06-07
Information query